Close Menu

NEW YORK (GenomeWeb) – Cowen and JP Morgan both initiated coverage of Twist Bioscience today, citing the company's leadership role in the synthetic biology market and its ability to manufacture DNA cheaply and at scale using its commercial platform.

While Cowen assigned the company's shares a rating of Outperform, JP Morgan analyst Tycho Peterson gave them a more conservative rating of Neutral, saying in a note to investors that the stock's value has essentially doubled after the firm's initial public offering, prompting JP Morgan to wait for a more opportunistic entry point.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

New analyses indicate the P.1 variant found in Brazil may be able to infect people who have already had COVID-19, the New York Times reports.

According to CNBC, Novavax's CEO says its vaccine could be authorized in the US as early as May.

The US National Institutes of Health has a new initiative to address structural racism in biomedical research.

In PNAS this week: GWAS of TLV-1-associated myelopathy/tropical spastic paraparesis, analysis of twins with hypertrophic cardiomyopathy, and more.